BioGend Therapeutics Co., Ltd.

Equities

6733

TW0006733009

Biotechnology & Medical Research

End-of-day quote Taipei Exchange Other stock markets 03:30:00 31/05/2024 am IST			5-day change	1st Jan Change
37 ^TWD	+1.37%		+1.51%	-3.27%

28/05	BioGend Therapeutics Co., Ltd. Announces Hsinchu Factory Pass the Domestic Medical Device Quality Management System Manufacturing License	CI
10/05	BioGend Therapeutics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

BioGend Therapeutics Co., LTD acquired Exactech Taiwan, Ltd.

December 31, 2017

BioGend Therapeutics Co., LTD acquired Exactech Taiwan, Ltd from Exactech, Inc. on December 31, 2017. BioGend Therapeutics Co., LTD completed the acquisition of Exactech Taiwan, Ltd from Exactech, Inc. on December 31, 2017.

Latest news about BioGend Therapeutics Co., Ltd.

BioGend Therapeutics Co., Ltd. Announces Hsinchu Factory Pass the Domestic Medical Device Quality Management System Manufacturing License	28/05	CI
BioGend Therapeutics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
BioGend Therapeutics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	02/03	CI
BioGend Therapeutics Co., Ltd. Receives Notification from the Thai FDA That Revocart to Obtains A Thai Medical Device License	06/02	CI
BioGend Therapeutics Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	07/11	CI
BioGend Therapeutics Co., Ltd.(TPEX:6733) added to S&P Global BMI Index	18/23/18	CI
BioGend Therapeutics Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/23/09	CI
BioGend Therapeutics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	13/23/13	CI
BioGend Therapeutics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	29/23/29	CI
BioGend Therapeutics Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	11/22/11	CI
BioGend Therapeutics Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	10/22/10	CI
BioGend Therapeutics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	11/22/11	CI
BioGend Therapeutics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	25/22/25	CI
BioGend Therapeutics Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	11/21/11	CI
Biogend Therapeutics Co., Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2021	10/21/10	CI
Biogend Therapeutics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	09/21/09	CI
Biogend Therapeutics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020	15/21/15	CI
Biogend Therapeutics Co., Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2020	09/20/09	CI
Biogend Therapeutics Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020	13/20/13	CI
Biogend Therapeutics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2019	28/20/28	CI
Biogend Therapeutics Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2019	07/19/07	CI
BioGend Therapeutics Completes Enrollment for The Pivotal Clinical Trial of One-Step Autologous Knee Cartilage Repair/Regeneration	26/18/26	CI
BioGend Therapeutics Co., LTD acquired Exactech Taiwan, Ltd.	31/17/31	CI

Chart BioGend Therapeutics Co., Ltd.

Duration

Period

More charts

Company Profile

BIOGEND THERAPEUTICS CO., LTD. is a medical equipment company mainly engaged in the development of biological aggregate. The Company is mainly engaged in the development and research of high-grade bone filling materials and knee cartilage repair related medical equipment. The Company's main products are BiG-001 which used for long bone biological aggregate, BiG-006 that used for lumbar interbody fusion biological bone, as well as BiG-009.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

37 TWD

Average target price

48 TWD

Spread / Average Target

+29.73%

Consensus

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BIOGEND THERAPEUTICS CO., LTD.	-3.27%	14Cr
MODERNA, INC.	+43.36%	5.46TCr
IQVIA HOLDINGS INC.	-5.31%	3.99TCr
LONZA GROUP AG	+37.52%	3.88TCr
ICON PUBLIC LIMITED COMPANY	+14.75%	2.69TCr
CELLTRION, INC.	-12.56%	2.62TCr
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	1.88TCr
UNITED THERAPEUTICS CORPORATION	+25.12%	1.22TCr
BIO-TECHNE CORPORATION	+0.04%	1.22TCr
MEDPACE HOLDINGS, INC.	+26.04%	1.19TCr

Other Biotechnology & Medical Research